Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy

David Stenehjem; Solomon Lubinga; Keith A. Betts; Wenxi Tang; Mads Jenkins; Yong Yuan; John Hartman; Sumati Rao; Jenny Lam; David Waterhouse

doi:10.2217/fon-2021-0230

Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy

David Stenehjem, Solomon Lubinga, Keith A. Betts, Wenxi Tang, Mads Jenkins, Yong Yuan, John Hartman, Sumati Rao, Jenny Lam, David Waterhouse

Duluth Pharmacy Program

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Background: Chemotherapy (CT) alone was previously standard first-line (1L) therapy for metastatic non-small-cell lung cancer (NSCLC) but alternative treatments, including immunotherapy (I-O), are now available. Patients and methods: In this retrospective study, adults with stage IV NSCLC who initiated 1L treatment between 1 August 2018 and 31 December 2019 and had ≥2 visits were identified in the Flatiron database. Patients were followed up until 30 June 2020. Baseline characteristics and treatment patterns were described by treatment group: CT, I-O + CT, I-O monotherapy and other. Results: Approximately 20% of patients received 1L CT in the 2018-2019 timeframe studied; these patients tended to have squamous histology and low (≤49%) programmed death ligand-1 expression. Conclusion: A proportion of patients with metastatic NSCLC still receive 1L CT despite the availability and widespread use of I-O therapies.

Original language	English (US)
Pages (from-to)	2940-2949
Number of pages	10
Journal	Future Oncology
Volume	17
Issue number	22
DOIs	https://doi.org/10.2217/fon-2021-0230
State	Published - Aug 2021

Bibliographical note

Funding Information:
Medical writing and editorial support was provided by Brooke Middlebrook, CMPP, Evidence Medical Affairs (PA, USA) and was funded by Bristol Myers Squibb.

Funding Information:
K Betts, W Tang and M Jenkins are employees of Analysis Group, which received research funding for the work under consideration. D Stenehjem has received personal fees from Bristol Myers Squibb, Dracen Pharmaceuticals, Iterion Therapeutics, Molecular Templates and Salarius Pharmaceuticals; grants from AstraZeneca, Bayer, Bristol Myers Squibb, Jazz Pharmaceuticals and Novartis. J Hartman, J Lam, S Lubinga, S Rao and Y Yuan are employees of Bristol Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Publisher Copyright:
© 2021 David Stenehjem and Bristol-Myers Squibb Company.

Keywords

immune checkpoint inhibitors
immunotherapy
non-small-cell lung cancer
real-world outcomes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.2217/fon-2021-0230

OpenUrl availability

Full text

Cite this

@article{81f7a60dd832436487ed9474ab905ca0,

title = "Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy",

abstract = "Background: Chemotherapy (CT) alone was previously standard first-line (1L) therapy for metastatic non-small-cell lung cancer (NSCLC) but alternative treatments, including immunotherapy (I-O), are now available. Patients and methods: In this retrospective study, adults with stage IV NSCLC who initiated 1L treatment between 1 August 2018 and 31 December 2019 and had ≥2 visits were identified in the Flatiron database. Patients were followed up until 30 June 2020. Baseline characteristics and treatment patterns were described by treatment group: CT, I-O + CT, I-O monotherapy and other. Results: Approximately 20% of patients received 1L CT in the 2018-2019 timeframe studied; these patients tended to have squamous histology and low (≤49%) programmed death ligand-1 expression. Conclusion: A proportion of patients with metastatic NSCLC still receive 1L CT despite the availability and widespread use of I-O therapies.",

keywords = "immune checkpoint inhibitors, immunotherapy, non-small-cell lung cancer, real-world outcomes",

author = "David Stenehjem and Solomon Lubinga and Betts, {Keith A.} and Wenxi Tang and Mads Jenkins and Yong Yuan and John Hartman and Sumati Rao and Jenny Lam and David Waterhouse",

note = "Funding Information: Medical writing and editorial support was provided by Brooke Middlebrook, CMPP, Evidence Medical Affairs (PA, USA) and was funded by Bristol Myers Squibb. Funding Information: K Betts, W Tang and M Jenkins are employees of Analysis Group, which received research funding for the work under consideration. D Stenehjem has received personal fees from Bristol Myers Squibb, Dracen Pharmaceuticals, Iterion Therapeutics, Molecular Templates and Salarius Pharmaceuticals; grants from AstraZeneca, Bayer, Bristol Myers Squibb, Jazz Pharmaceuticals and Novartis. J Hartman, J Lam, S Lubinga, S Rao and Y Yuan are employees of Bristol Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2021 David Stenehjem and Bristol-Myers Squibb Company.",

year = "2021",

month = aug,

doi = "10.2217/fon-2021-0230",

language = "English (US)",

volume = "17",

pages = "2940--2949",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "22",

}

TY - JOUR

T1 - Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy

AU - Stenehjem, David

AU - Lubinga, Solomon

AU - Betts, Keith A.

AU - Tang, Wenxi

AU - Jenkins, Mads

AU - Yuan, Yong

AU - Hartman, John

AU - Rao, Sumati

AU - Lam, Jenny

AU - Waterhouse, David

N1 - Funding Information: Medical writing and editorial support was provided by Brooke Middlebrook, CMPP, Evidence Medical Affairs (PA, USA) and was funded by Bristol Myers Squibb. Funding Information: K Betts, W Tang and M Jenkins are employees of Analysis Group, which received research funding for the work under consideration. D Stenehjem has received personal fees from Bristol Myers Squibb, Dracen Pharmaceuticals, Iterion Therapeutics, Molecular Templates and Salarius Pharmaceuticals; grants from AstraZeneca, Bayer, Bristol Myers Squibb, Jazz Pharmaceuticals and Novartis. J Hartman, J Lam, S Lubinga, S Rao and Y Yuan are employees of Bristol Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2021 David Stenehjem and Bristol-Myers Squibb Company.

PY - 2021/8

Y1 - 2021/8

N2 - Background: Chemotherapy (CT) alone was previously standard first-line (1L) therapy for metastatic non-small-cell lung cancer (NSCLC) but alternative treatments, including immunotherapy (I-O), are now available. Patients and methods: In this retrospective study, adults with stage IV NSCLC who initiated 1L treatment between 1 August 2018 and 31 December 2019 and had ≥2 visits were identified in the Flatiron database. Patients were followed up until 30 June 2020. Baseline characteristics and treatment patterns were described by treatment group: CT, I-O + CT, I-O monotherapy and other. Results: Approximately 20% of patients received 1L CT in the 2018-2019 timeframe studied; these patients tended to have squamous histology and low (≤49%) programmed death ligand-1 expression. Conclusion: A proportion of patients with metastatic NSCLC still receive 1L CT despite the availability and widespread use of I-O therapies.

AB - Background: Chemotherapy (CT) alone was previously standard first-line (1L) therapy for metastatic non-small-cell lung cancer (NSCLC) but alternative treatments, including immunotherapy (I-O), are now available. Patients and methods: In this retrospective study, adults with stage IV NSCLC who initiated 1L treatment between 1 August 2018 and 31 December 2019 and had ≥2 visits were identified in the Flatiron database. Patients were followed up until 30 June 2020. Baseline characteristics and treatment patterns were described by treatment group: CT, I-O + CT, I-O monotherapy and other. Results: Approximately 20% of patients received 1L CT in the 2018-2019 timeframe studied; these patients tended to have squamous histology and low (≤49%) programmed death ligand-1 expression. Conclusion: A proportion of patients with metastatic NSCLC still receive 1L CT despite the availability and widespread use of I-O therapies.

KW - immune checkpoint inhibitors

KW - immunotherapy

KW - non-small-cell lung cancer

KW - real-world outcomes

UR - http://www.scopus.com/inward/record.url?scp=85111003464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111003464&partnerID=8YFLogxK

U2 - 10.2217/fon-2021-0230

DO - 10.2217/fon-2021-0230

M3 - Article

C2 - 33849296

AN - SCOPUS:85111003464

SN - 1479-6694

VL - 17

SP - 2940

EP - 2949

JO - Future Oncology

JF - Future Oncology

IS - 22

ER -

Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this